Yulia Slavina

Tau proteoform quantification research unveiled by Nautilus Biotechnology at ASMS2026

Tau proteoform quantification research unveiled by Nautilus Biotechnology at ASMS2026
Nautilus unveils Tau quantification

Nautilus Biotechnology announced that its Senior Director of Scientific Affairs and Alliance Management, Andreas Huhmer, will deliver a poster presentation (#644) at ASMS2026, focusing on high-accuracy single-molecule quantification of Tau proteoforms across isoforms and phosphorylation sites.

The research highlights advances in measuring Tau proteins, which play a critical role in neurodegenerative diseases such as Alzheimer disease. The presentation demonstrates the company’s progress in proteomics, showcasing innovative methods for identifying and quantifying complex protein forms that could impact future diagnostic technologies. Details of the study are available through the company’s latest communications from the conference.

Nautilus previously launched its Voyager Platform at Tau Global 2026, enabling quantification of 768 tau proteoforms at the event. The company has also shared advances in single molecule proteomics with its Voyager platform at ASMS, where experts were available for discussions during the conference. These developments reflect the company's continued focus on proteomic technologies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.